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ABSTRACT
Human ERCC1/XPF is a structure-specific endonu-
clease involved in multiple DNA repair pathways. We
present the solution structure of the non-catalytic
ERCC1 central domain. Although this domain shows
structural homology with the catalytically active XPF
nuclease domain, functional investigation reveals
a completely distinct function for the ERCC1 central
domain by performing interactions with both XPA
and single-stranded DNA. These interactions are
non-competitive and can occur simultaneously
through distinct interaction surfaces. Interestingly,
the XPA binding by ERCC1 and the catalytic function
of XPF are dependent on a structurally homologous
region of the two proteins. Although these regions
are strictly conserved in each protein family, amino
acid composition and surface characteristics are
distinct. We discuss the possibility that after XPF
gene duplication, the redundant ERCC1 central
domain acquired novel functions, thereby increas-
ing the fidelity of eukaryotic DNA repair.
INTRODUCTION
During DNA replication, recombination and repair,
double-stranded DNA inevitably forms three- or four-
way junctions, bubbles, ﬂaps or broken ends with single-
stranded extensions. These irregular structures must be
processed correctly in order to successfully complete
DNA metabolism and thereby maintain genome integrity.
This task is accomplished by structure-speciﬁc endonu-
cleases specialized in pruning downstream of branch, ﬂap
or bubble structures by incision at junctions between
double- and single-stranded DNA (1). Inactivation or
malfunctioning of these enzymes causes genetic defects or
cancer, underlying their importance in genome stability.
A remarkable class of structure-speciﬁc endonucleases
in humans is XPF. The protein family is characterized
by the presence of the ERCC4 domain and consists of
seven members (XPF, MUS81, ERCC1, EME1, EME2,
FANCM and FAAP24) (2). Only XPF and MUS81
have nuclease activity, which is mediated by the conserved
core nuclease motif (ERKX3D) (3–5). Their catalytic
function depends on heterodimer formation with the
non-catalytic family members. XPF forms an obligate
complex with ERCC1 and functions primarily in nucleo-
tide excision repair (NER), a versatile pathway able
to detect and remove a variety of DNA lesions induced
by UV light and environmental carcinogens. The
ERCC1/XPF heterodimer has additional roles in DNA
interstrand cross-link (ICL) repair (6) and telomere
maintenance (7). The symptoms of the ﬁrst patient with
inherited ERCC1 deﬁciency (8) and of a patient with a
novel XPF mutation (9) are distinct from the classical
NER phenotype, and underscore the pleiotropic function
of ERCC1/XPF.
In contrast to eukaryotes, archaea have a single
homolog of the XPF endonuclease that forms homo-
dimers. The archaeal XPF minimally consists of the
catalytic nuclease domain followed by a DNA-binding
domain containing two consecutive helix-hairpin-helix
motifs (HhH2 domain). Dimerization occurs between
both the nuclease and HhH2 domains of each subunit
(Figure 1A) (3). The strong preference of the archaeal
endonucleases for 30 ﬂap DNA substrates is explained by
the function of their individual domains. Structural data
suggest a model for DNA binding where one HhH2
domain of the dimer binds to an upstream and the other to
a downstream DNA duplex, sharply bending the DNA
substrate and thereby allowing one active site of the
dimeric nuclease domain to cleave the 30 protruding single
strand (10). Combination of mutations in nuclease and
HhH2 domains that do not disrupt the dimeric interfaces
but impair the individual functions (DNA cleavage or
DNA binding), provide evidence for this model (11).
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The DNA substrate speciﬁcity is diﬀerent for the human
ERCC1/XPF heterodimer. The human enzyme is known
to speciﬁcally incise hairpin, bubble or splayed-arm DNA
substrates (12,13), which consist of only one duplex
(upstream). Previous data indicated the role of the
C-terminal ERCC1 ‘canonical’ HhH2 domain in engaging
the upstream DNA duplex of a hairpin substrate (14).
This function requires heterodimerization with the
C-terminal HhH domain of the human XPF partner to
form a complex analogous to the archaeal HhH2 dimer
interface (12,14). Previous structural data (12) and the
data presented here illustrate the structural similarity
between the human ERCC1 central domain and the
archaeal XPF nuclease domain. Unlike the archaeal
nuclease dimer interface, there is no evidence that the
corresponding domains of human ERCC1 and XPF
interact with each other in solution (Figure 1A) (12).
The catalytic function of the ERCC1/XPF endonu-
clease is crucial for NER. NER operates through a ‘cut
and patch’ mechanism by excising and removing a short
stretch of DNA containing the lesion, and subsequently
restoring the genetic information by repair synthesis using
the undamaged strand as the template. The incision step
involves the sequential and coordinated assembly of the
DNA damage sensor XPC-HR23B, the transcription/
repair factor TFIIH, the architectural protein XPA, the
ubiquitous ssDNA-binding protein RPA, and the two
structure-speciﬁc endonucleases ERCC1/XPF and XPG,
responsible for the incisions 50 and 30 to the damaged site,
respectively (15). A main role in the progress of the
reaction is attributed to XPA, which in complex with RPA
probes the DNA helix conformations (16) and participates
in multiple interactions with the other NER factors (15).
XPA is required for the recruitment of ERCC1/XPF in the
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Figure 1. (A) Domain organization of the archaeal XPF homodimeric members and the human ERCC1/XPF heterodimer. (B) Structure-based
sequence alignment of the nuclease XPF domains from archaea to human and the corresponding central domain of human ERCC1. Secondary
structure elements of the prototype XPF nuclease fold are indicated at the top of the sequences. Catalytic residues in the XPF nucleases are colored
red and their corresponding substitutions in ERCC1 blue. Other invariant residues in XPF domains are depicted in orange, while the ERCC1
equivalents are depicted in cyan. Residues of cERCC1 perturbed largely upon XPA titration are indicated by blue triangles and those appear only in
the ﬁnal complex by brown ellipses. Green asterisks indicate cERCC1 residues perturbed by DNA titration. cERCC1 sequence is numbered at the
bottom. (C) Ensemble of the ﬁnal 20 structural conformers of cERCC1 as determined by solution NMR. Secondary structure elements and N- and
C-termini are labeled. (D) Superposition of the crystal XPF nuclease structure (2bgw) from A. pernix (purple) and the solution NMR structure (2jpd)
of human cERCC1 (yellow). Emphasis is given to the nuclease signature and the corresponding substitutions in cERCC1.
5790 Nucleic Acids Research, 2007, Vol. 35, No. 17
NER pre-incision complex (17,18). Consistent with this
regulatory function, in vitro studies with recombinant
proteins and in vivo studies using a yeast two-hybrid
system have demonstrated interactions between XPA and
ERCC1 (19).
Here, we report the solution structure of the ERCC1
central domain (cERCC1) and investigate its interactions
with XPA and DNA at the molecular level. Using
biochemical studies and NMR titration experiments,
we have identiﬁed two distinct interaction surfaces
of cERCC1 that mediate XPA and DNA binding.
Interestingly, the two interactions can take place simulta-
neously to yield a cERCC1/DNA/XPA ternary complex,
which in turn explains the important role of ERCC1
in targeting its catalytic XPF partner to the NER
pre-incision complex.
MATERIALS AND METHODS
Cloning, protein expression and protein purification
ERCC1 central domain (cERCC1, residues 96 to 219) was
PCR-ampliﬁed from a vector containing the full-length
ERCC1 gene and subcloned into a pET28b (Novagen)
expression vector between BamHI and XhoI sites.
Downstream of the XhoI site a linker together with a
his-tag has been engineered. XPA constructs were derived
from a full-length XPA vector purchased from RZPD
(clone ID IRAUp969B1273D6) and subcloned into
a pLICHIS vector using the enzyme free cloning
(EFC) strategy (20). The same procedure was followed
for the GST fusion proteins, either XPA or cERCC1
(pLICHISGST vector). As a result all the EFC constructs
contain an N-terminal his-tag, while the cERCC1
construct bears a C-terminal his-tag. The nucleotide
sequences of the cloned DNAs were conﬁrmed by
sequencing. The cERCC1-HIS, HIS-XPA, HIS-GST-
XPA and HIS-GST-cERCC1 proteins were expressed in
BL21(DE3) Rosetta cells (Novagen) and were subject
to two-step puriﬁcation as has been described (21).
When appropriate, HIS-GST-cERCC1 was cleaved with
thrombin in the presence of 1mM Ca2+, 50mM Tris
(pH 8.0) and 100mM NaCl in order to obtain the
untagged protein. Finally, the protein samples were
exchanged either to 50mM sodium phosphate (pH 5.5),
100mM NaCl for the cERCC1 structure determination,
or to 50mM Tris (pH 8.0), 100mM NaCl for the binding
studies.
NMR spectroscopy
Multidimensional NMR experiments were carried out
at 290K on Bruker AVANCE 600 and 900 NMR
spectrometers equipped with TXI triple-resonance
probes in 50mM sodium phosphate (pH 5.5), 100mM
NaCl by using the cERCC1-HIS protein. Spectra were
processed using the NMRPipe software package (22) and
analyzed with Sparky (23). The 1H, 15N and 13C resonance
assignments are 97% complete and were made using
standard triple resonance techniques, 3D NOESY-
(15N, 1H)-HSQC spectra, and 3D NOESY-(13C, 1H)-
HSQC spectra (both with a mixing time of 60ms) (24).
The chemical shifts have been deposited at the BMRB
with accession number 15240.
Structure calculations
Automatic NOE assignment and structure calculations
were performed using the program CYANA version 2.0
(25). Hydrogen bond restraints were deﬁned when they
were consistent with the secondary chemical shift data and
expected NOE contacts and only for the helical parts of
the protein. The set of 2669 NOE restraints determined
by CYANA, together with restraints for 31 hydrogen
bonds and f and c torsion angle restraints (174) derived
from TALOS (26) were used in a water reﬁnement run
according to the standard RECOORD protocol (27)
utilizing CNS (28). Molecular images were generated
with PyMol (29). Coordinates have been deposited at the
PDB with accession code 2jpd and the structural restraints
at the BMRB with entry number 15240.
EMSAs
All the DNA substrates were 50 32P-labeled with T4
polynucleotide kinase and puriﬁed on a polyacrylamide
gel under native conditions. The nucleotide sequences for
ss20, b10 and ds30 have been described before (30). Per
reaction, 100 fmol of substrate was incubated with the
appropriate amount of ERCC1 protein in binding buﬀer
(50mM Tris, pH 8.0, 100mM NaCl, 10% glycerol and
1mg/ml BSA). After incubation for 30min at 48C,
samples were loaded onto 7.5% native polyacrylamide
gels containing 0.5 TBE and run at 48C. Alternatively
Electrophoretic mobility shift assay (EMSA) reactions
were loaded on a 3.5% agarose gel containing 0.5% TBE,
run at 4 or 208C yielding essentially identical results.
Gels were visualized and quantiﬁed using a phosphor
imager (BioRad) as described before (30). For depletion
experiments, 20 ml of MagneHis beads (Promega) or GST
agarose beads (Sigma), were extensively washed with
binding buﬀer, and after buﬀer removal the EMSA
reaction was added to the beads. After 15min incubation
with regular mixing, the beads were removed from the
EMSA reaction using a magnet or centrifugation and the
reaction mixture was loaded on acrylamide gel or, when
appropriate, the substrate was added to the depleted
reaction mixture.
GST pull-down assay
GST pull-down assay was performed and quantiﬁed as
described before (31) using the indicated cERCC1
concentrations and 3–5mg of GST proteins in 150 ml of
50mM Tris, 100mM NaCl, 10% glycerol, 1mM DTT,
0.2mM PMSF and 20mg/ml of BSA (pH 8.0). The semi-
quantitative experiments were performed in 50, 150, 500,
1500 and 5000ml buﬀer with a constant amount of
cERCC1 and GST-XPA.
NMR titrations
cERCC1 titrations with XPA and DNA were performed
on a Bruker AVANCE 700 NMR spectrometer and were
monitored with 2D 1H-15N HSQC experiments. In all
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cases, the concentration of cERCC1 was 0.2mM in
50mM Tris (pH 8.0), 100mM NaCl. XPA and DNA
were dissolved in the same buﬀer and therefore salt and
pH did not vary throughout the experiments. DNA
binding was feasible only with the cERCC1 construct
lacking the C-terminal his-tag, while XPA binding was
identical, regardless of the his-tag presence. Normalized
chemical shift changes were calculated by using the
equation: =([HN]
2+ [N/6]
2)0.5.
RESULTS AND DISCUSSION
Structure analysis
We have determined the solution structure of the ERCC1
central domain (cERCC1) to elucidate the molecular
details of its proposed functions. We have collected a large
number of distance and dihedral angle restraints that
yielded an ensemble of 20 conformers with very good
convergence (Figure 1C). The quality of the structure can
be judged by the summary of the structural and restraint
statistics given in Table 1. All the secondary structure
elements are well deﬁned including the short loops that
join them. cERCC1 comprises a compact architecture and
folds as a six-stranded b-sheet ﬂanked by ﬁve a-helices
on both sides. As described before (12), this fold is
reminiscent of the type II restriction endonucleases, to
which the catalytic domain of XPF also belongs.
Overall, the solution NMR structure of cERCC1 is in
very good agreement with the crystal structure of the same
domain (2a1i) (rmsd 1.1 A˚ for 108Ca atoms). The only
noticeable diﬀerence relates to the last few residues of
helix a3 and the loop connecting this structure element
with b5. The presence of a mercury atom (linked to C137)
in the crystal structure may account for the substantial
side-chain rearrangements within this loop. When com-
pared to the crystal structures of the archaeal nucleases,
helices a1, a2, and strands b1, b2 appear to be shorter in
the solution structure of cERCC1. Solution cERCC1 and
the crystal structures of archaeal XPF nucleases (2bgw
and 1j23) contain the same number of secondary structure
elements arranged in a very similar manner (rmsd 1.8
and 2.0 A˚ for Aeropyrum pernix and Pyrococcus furiosus
nucleases, respectively, for 108Ca atoms), although in
both cases the primary sequence homology is very low
(Figure 1B and D).
Remarkably, conserved residues of XPF nuclease
scattered in the primary sequence superimpose structurally
with residues conserved in the ERCC1 sequence family
(Figures 1 and 3). Whereas the conservation in XPF is
directly related to the catalytic function, ERCC1 has
preserved the same fold but lacks the essential residues
for catalysis. The fold similarities, coupled with the
obligate nature of the heterodimerization (32), are in
full agreement with the common origin of the two
proteins (33).
Minimal domains for ERCC1–XPA interaction
Truncation studies of ERCC1 have mapped the XPA
interaction site to a region between residues 91 and 118
(34). From the cERCC1 structure and its compact fold, we
predict that such truncations will have a devastating eﬀect
on the structural integrity of the central domain (96–219).
For XPA, the ERCC1 interaction region seems to be
located in a small stretch containing two highly conserved
motifs rich in glycine and glutamic acid residues
(72-GGGFILEEEEEEE-84, conserved residues are
underlined) (19). We have prepared a HIS-GST-XPA
construct (59–99) containing the conserved stretch, and
examined its ability to interact with cERCC1 in a GST
pull-down assay. Indeed, the GST XPA fusion protein was
able to speciﬁcally bind cERCC1 (Figure 2A), conﬁrming
that this domain of ERCC1 is suﬃcient for interactions
with XPA. No binding of cERCC1 to GST bound agarose
beads or uncharged agarose beads was observed
(Figure 2A, data not shown). This XPA peptide is
unstructured (35) and appeared very sensitive to proteo-
lysis both during overexpression in Escherichia coli and as
pure protein after extensive puriﬁcation (Figure 2A and
B). We next performed a semi-quantitative GST pull-
down assay (31) and estimated an apparent Kd of 1 mM.
Since we reached only 20% binding saturation at the two
highest protein concentrations (3 and 10 mM of cERCC1)
under these experimental conditions, we could not
determine the binding constant more accurately
(Figure 2B).
Functional disparity of the XPF nuclease and ERCC1 central
domains
The cERCC1–XPA interaction speciﬁcity has been
explored using NMR titration experiments. Titration
with the HIS-XPA peptide causes extensive speciﬁc
Table 1. Structural statistics of the structure ensemble of human
cERCC1 (residues 96–219)
Rmsd (A˚) with respect to meana
Backbone/Heavy atoms 0.40 0.04/0.89 0.08
Number of experimental restraints
Intraresidue NOEs 632
Sequential NOEs (|i j|=1) 678
Medium range NOEs (15|i j|54) 479
Long-range NOEs (|i j|44) 880
Total NOEs 2669
Dihedral angle restrains 174
Hydrogen bonds 31
Restraint violations
NOE distances with violations40.3 A˚ 0.00 0.00
Dihedrals with violations438 0.00 0.00
Rmsd for experimental restraints
All distance restraints (2669) (A˚) 0.013 0.005
Torsion angles (174) (8) 0.579 0.077
CNS energies after water reﬁnement
Evdw (kcal/mol) 614 17
Eelec (kcal/mol) 4914 61
Rmsd from idealized covalent geometry
Bonds (A˚) 0.01 0.00
Angles (8) 1.15 0.03
Impropers (8) 1.34 0.06
Ramachandran analysis
Residues in the favored regions (%) 90.68 2.04
Residues in additional allowed regions (%) 8.16 1.71
Residues in generously allowed regions (%) 0.81 0.65
Residues in disallowed regions (%) 0.36 0.68
aResidues 101–215 of cERCC1.
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changes in the cERCC1 1H-15N HSQC NMR spectra.
The titrations show slow exchange regime with respect to
the NMR chemical shift timescale, in agreement with the
determined aﬃnity (Figure 2C). We have been able to
assign all the amide resonances of cERCC1 in the bound
form (1:1 complex stoichiometry) by using 3D NOESY-
(15N, 1H)-HSQC spectra. The pattern of the backbone
amide NOEs does not change substantially compared to
the free cERCC1 protein. This indicates that the overall
structure is maintained, and led us to conclude that the
observed chemical shift perturbations arise from speciﬁc
contacts with the XPA peptide.
The most signiﬁcant perturbations map to the surface
of the V-shaped groove of the cERCC1 structure and
involve many residues that compose the corresponding
DNA cleavage site of the archaeal XPF endonucleases
(Figures 2D and 3). Interestingly, among the largest
chemical shifts of cERCC1 upon XPA binding are those
of L139, F140 and L141. These ERCC1 residues
correspond to the characteristic strongly conserved ERK
catalytic triad of the XPF nuclease domain (Figure 1). The
rest of the signiﬁcantly perturbed residues are polar or
positively charged (Q107, N110, S142, R144, N147 and
R156), are competent for hydrogen bonding with the
XPA peptide and are more conserved than the surround-
ing regions of the cERCC1 V-shaped groove (Figure 3).
Additionally, of special interest are the amide signals of
G109 and H149, which are not observed in the free protein
spectrum due to fast exchange with the solvent at pH 8
(these amide resonances are observable at pH 5.5).
However, both give sharp signals at the end of the
titration, an indication that the solvent exchange in the
free protein is quenched in the complex. These residues
reside at the rim of the V-shaped binding site and may
be involved in hydrogen bonding with the XPA peptide
(Figure 3).
Although ERCC1 residues forming the XPA-binding
site are diﬀerent from the acidic and basic residues which
form the active site in XPF (5), there are no signiﬁcant
changes in the backbone fold and the spatial side-chain
orientations in the structure remain unaﬀected. However,
their diﬀerent chemical properties result in a distinct
charge and hydrophobicity distribution on the structure
surface (Figure 3). While XPF displays negative charge
at the DNA cleavage site (important for divalent
cation coordination), the equivalent XPA-binding site
in ERCC1 is neutral or slightly positively charged.
Therefore, the ERCC1–XPA interaction is a combination
of hydrophobic and electrostatic interactions possibly
involving the glutamic acid stretch of XPA (19) and two
conserved positively charged residues (R106 and R156)
of cERCC1.
DNA binding by the ERCC1 central domain
Given the proposed common origin of ERCC1 and XPF
(33), it can be expected that the degenerated catalytic site
of ERCC1 could still bind DNA in a similar fashion as the
archaeal XPF active site (12). Because our ERCC1–XPA
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Figure 2. ERCC1–XPA interactions. (A) GST pull-down assay with 3 mg of GST or GST-XPA fusion proteins in the presence or absence of 2 mM
cERCC1. Here, 0.2 and 0.04 refer to respectively 20 and 4% of the input cERCC1 protein present in the GST pull-down assay. (B) Semi quantitative
GST pull-down assay showing the fraction of cERCC1 bound to 3mg of GST-XPA at the indicated [cERCC1] (mM). The upper part of inset shows a
representative GST pull-down assay, where the various cERCC1 concentrations used are depicted above (10, 3, 1, 0.3 and 0.1 mM). The lower panel
shows respectively 100, 20 and 4% of cERCC1 added to the assay. (C) Chemical shift perturbation of the cERCC1 1H-15N HSQC upon complex
formation with XPA. Free cERCC1 spectrum is in black and XPA-bound spectrum in blue, while brown circles in the bound spectrum indicate
G109 and H149 resonances. (D) Normalized chemical shift changes between free and XPA-bound forms versus the cERCC1 sequence. The p.p.m.
diﬀerence for G109 and H149 was calculated by their resonances in the free cERCC1 spectrum at pH 5.5, and are colored brown.
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interaction data render this unlikely, we explored whether
cERCC1 is able to bind DNA as has been suggested
previously (12).
We performed an electrophoretic mobility shift assay
(EMSA) where increasing amounts of cERCC1-HIS
protein were added to ssDNA. While we saw a loss of
free probe, we failed to see any complex formation under
these conditions. If the same protein–DNA complex was
loaded on a 3.5% agarose gel, we detected a weak smeary
complex at the highest protein concentration (Figure 4A).
However, by using a HIS-GST-cERCC1 protein, we
observed formation of the complex with ssDNA
(Figure 4B). This suggests that the C-terminal his-tag
interferes with DNA binding. Therefore, we used the HIS-
GST-cERCC1 protein, which we cleaved with thrombin to
obtain the untagged protein. DNA binding with the
untagged cERCC1 demonstrated a faster migrating
complex with various ssDNA substrates (data not
shown). HIS-GST-cERCC1/DNA complex formation is
prevented by incubation of the reaction mixture with
MagneHIS magnetic beads or glutathione agarose beads,
which depletes HIS-GST-cERCC1 from the reaction
mixture either prior to or after the addition of DNA.
If beads were added after complex formation, a small
but signiﬁcant decrease in the amount of free probe
was observed. Depletion of the HIS-GST tagged cERCC1
protein from the binding reaction conﬁrms that
the protein–DNA complex is indeed formed by the
HIS-GST-cERCC1 protein (Figure 4C).
In agreement with earlier studies, under these condi-
tions no binding was observed for dsDNA (12), while
fairly comparable binding aﬃnities were found for both
ssDNA and bubble substrates with 10 or 20 unpaired
bases. We calculated an apparent Kd of 2.5 0.7 mM for
the HIS-GST-cERCC1 protein bound to a bubble10 (b10)
substrate in the presence of 100mM NaCl (Figure 4B).
Corroborating our results, an equilibrium binding titra-
tion experiment using ﬂuorescence anisotropy has demon-
strated ssDNA binding for the same domain with an
apparent Kd of 10 mM (12). The relatively small diﬀerence
in aﬃnity can be well explained by diﬀerent salt conditions
or substrate used.
For the NMR titrations we performed a thrombin
cleavage on HIS-GST-cERCC1, to remove the his-tag.
The untagged cERCC1 1H-15N HSQC spectrum is
identical to that of cERCC1-HIS, except for the two
amides preceding the artiﬁcial his-tag (Supplementary
Figure 1). Addition of the b10 substrate to this cERCC1
protein caused a limited number of speciﬁc perturbations
that were unambiguously assigned. Again, the perturbed
resonances exhibit slow exchange behavior in the NMR
titrations and indicate contacts with the DNA. The
aﬀected resonances include the backbone amides of
N99, I102, L132, K213, A214 and the side-chain amide
of Q134 (Figure 4D and E). Compared to the free-protein
spectrum we only miss T211, which cannot be identiﬁed.
The perturbation induced by the b10 DNA was complete
at equimolar concentration with cERCC1. Chemical shift
mapping reveals that all perturbations are in the vicinity
of the C-terminus of the cERCC1 construct, consistent
with the presence of a ﬂexible tag interfering with DNA
binding. The DNA-binding region resides at the surface
of the structure where the N- and C-termini meet
(Figure 4F). The perturbed residues belong to well-deﬁned
structure elements. The only positively charged residue we
identiﬁed (K213) is fully conserved in the ERCC1 proteins
and may explain the dependence of DNA binding on salt
concentration. All the other aﬀected residues are less
conserved than the residues involved in XPA binding.
The composition of the aﬀected residues together with the
XPF active site
XPA binding site
H149
G109
ERCC1
hydrophobicityconservation electrostatics functionfold
Figure 3. Common fold, diﬀerent properties and distinct functions for XPF and ERCC1. Sequence conservation either for XPF or ERCC1 proteins
is colored from white (non-conserved) to red (highly conserved). The opposite face has no signiﬁcant conservation for either protein. Hydrophobic
side chains are colored orange. Electrostatic surface potentials were calculated using APBS (39) and colored blue for positive or red for negative
charge potential. Active site residues of XPF were chosen based on previous mutational studies (5) and the XPA-binding site of ERCC1 was
identiﬁed by our NMR titrations.
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Figure 4. DNA binding by cERCC1. (A) EMSA with a 20-mer ssDNA substrate using increasing concentrations of cERCC1-HIS protein (0, 0.04,
0.2, 1, and 5 mM), loaded on a 7.5% acrylamide gel (upper panel) or a 3.5% agarose gel (lower panel). (B) EMSA using ssDNA (20-mer), dsDNA
(30 bp) and bubble10, a dsDNA with 10 unpaired bases as substrate, in the presence of 0, 0.125, 0.25, 0.5 and 1mM HIS-GST-cERCC1.
(C) Inhibition of cERCC1–b10 DNA complex formation ([cERCC1]=0.5 mM) by depletion of HIS-GST-cERCC1 from the EMSA reaction by the
addition of MagneHis beads (H) or GST agarose beads (G) prior to or after addition of DNA (italic). F: free DNA, C: cERCC1–DNA complex.
(D) Chemical shift perturbation after addition of b10 DNA. The spectrum of the free protein is shown in black and the spectrum after addition
of equimolar amount of b10 in green. (E) Normalized chemical shift changes between free and b10-bound forms versus the cERCC1 sequence.
(F) Surface and cartoon representations of cERCC1 colored according to normalized chemical shifts. Yellow star indicates the position of the
C-terminal his-tag that was interfering with DNA binding.
Nucleic Acids Research, 2007, Vol. 35, No. 17 5795
slow exchange behavior suggests a large contribution to
the binding by hydrophobic interactions with the DNA
bases.
Summarizing, both the biochemical and the NMR
experiments show that the ERCC1 central domain binds
to DNA. The DNA-binding site we identiﬁed on cERCC1
by the NMR titrations suggests that cERCC1 contacts
only a small part of the ssDNA, probably three to four
bases. The situation is diﬀerent in the full-length
heterodimer, where other DNA-binding surfaces, such as
previously established for the C-terminal ERCC1/XPF
domains (12,14), assist in DNA recognition.
cERCC1 can bind simultaneously to XPA and ssDNA
Chemical shift perturbation experiments revealed distinct
binding surfaces for ssDNA and XPA, and therefore, it is
probable that both can bind simultaneously to cERCC1.
We performed EMSA experiments in the presence of
an equimolar or 5-fold excess of the HIS-XPA peptide.
Addition of XPA did not inﬂuence binding of cERCC1 to
ssDNA, while the binding aﬃnity of XPA for the cERCC1
domain under these conditions would suggest that the vast
majority of cERCC1 is in complex with XPA. We did
not observe formation of a slower migrating HIS-GST-
cERCC1/ssDNA/XPA super complex, possibly because
the increase in mass by the addition of the HIS-XPA
peptide was too small to discern (data not shown).
To independently conﬁrm the formation of a ternary
cERCC1/ssDNA/XPA complex, we added the HIS-XPA
peptide to the cERCC1-bubble10 protein–DNA complex
and followed the chemical shift perturbations in the
1H-15N HSQC spectra. As shown in Figure 5, addition of
an equimolar amount of the XPA peptide causes the same
amide displacements as in the titration with the free
protein. On the contrary, most amides inﬂuenced by the
DNA binding remain unaﬀected by the presence of XPA
(Figure 5A). I102 and N110 were perturbed by both
XPA and b10 DNA when the titrations were performed
independently. In the ternary complex, however, I102
remains close to the position as in the DNA bound form.
Conversely, the side-chain amide of N110, although
aﬀected by the DNA, adopts the distinct XPA bound
position upon XPA addition. These data strongly indicate
the formation of the ternary ERCC1/DNA/XPA complex.
DNA and XPA-binding sites are distinct, and the two
interactions can happen simultaneously (Figure 5B).
Functional role of the ERCC1 central domain in the
heterodimer
Since the catalytic activity has been preserved in the
human XPF protein through strong conservation of the
nuclease signature (5), the human nuclease fold should be
identical to that of the archaeal counterparts. In that
sense, human XPF nuclease and human ERCC1 central
domains are expected to exhibit the same fold. Moreover,
the ERCC1 and XPF HhH2 domains feature a common
architecture and come into tight association exactly in the
same way that the HhH2 domains of both archaeal species
do (10,11,14). Therefore, in structural terms the human
ERCC1 and XPF proteins share the essential architectural
subunits observed in the short XPF homodimer of
A. pernix. The structural similarities within the XPF
family provide additional evidence for the proposed
common origin of the human ERCC1 and XPF proteins
(33). Because ERCC1 is absent in archaea, this gene is
thought to have been acquired from an ancient XPF gene
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Figure 5. Dual function of cERCC1. (A) Indicative portions of the 1H-15N HSQC spectrum for the free cERCC1, bound to either XPA (1:1) or
DNA (1:1) separately, and the ternary complex (1:1:1). (B) Views of the two binding sites on cERCC1 structure.
5796 Nucleic Acids Research, 2007, Vol. 35, No. 17
duplication in the eukaryal lineage. The ERCC1 and XPF
genes have subsequently evolved by the process called
subfunctionalization (36,37). This model suggests that
after gene duplication, both copies may be reciprocally
preserved through the ﬁxation of complementary loss-of-
subfunction mutations, which results in a partitioning of
the tasks of the ancestral gene. From the functions present
in the ancestral XPF protein (archaea), human ERCC1
retained the canonical HhH2 domain that acts as a DNA-
binding domain (14), while XPF retained the catalytic
activity (5). Once the separation of the ancestral subfunc-
tions occurred in ERCC1 and XPF genes, only the
heterodimeric protein complex could restore the original
function. Additionally, due to genetic alterations, the
second helix-hairpin-helix motif of human XPF degener-
ated, yet the fold remained crucial for stabilizing the
corresponding intact domain of human ERCC1 (14).
Similarly, the central domain of ERCC1 lost the catalytic
activity by sequence drift, but despite adoption of a novel
dual function (XPA interaction and DNA binding), the
3D fold was preserved.
We suggest a mechanistic model for the heterodimeric
function based on the model for the homodimeric archaeal
homolog (Figure 6) (10,38). Human ERCC1 corresponds
to the archaeal protomer that binds with the HhH2
domain to the upstream duplex. Human XPF corresponds
to the archaeal protomer that recognizes the downstream
duplex. Since it cannot make contacts with the minor
groove (14), the speciﬁcity of the human heterodimer has
shifted to splayed-arms substrates consisting of only one
duplex. This does not exclude contribution of the XPF
HhH domain to ssDNA interactions, as reported before
(12). We show here that the central domain of ERCC1
is also involved in ssDNA binding. Additional DNA
interactions are likely for the nuclease of XPF, analogous
to the archaeal case (38). Furthermore, ssDNA binding by
cERCC1 will be stimulated by speciﬁc interactions with
XPA, already present in the NER pre-incision complex
and possibly bound to the DNA via its own DNA-binding
site. Most importantly, through these coordinated inter-
actions of the ERCC1 domains the XPF protein will be
positioned to cleave the 30 protruding strand (limon),
thereby retaining the polarity present in the archaeal
homodimer.
Our model underlines the signiﬁcant role of ERCC1 in
the context of the full-length heterodimer. XPF is the
catalytic module but the ERCC1 domains guarantee that
the enzymatic activity is targeted properly. The presence
of multiple distinct DNA-binding surfaces within the
ERCC1/XPF/XPA/RPA repair protein intermediate
coordinates cleavage to occur only when the DNA
damage is recognized correctly by the NER machinery.
The duplication of the ancestral XPF gene within the
eukaryal kingdom resulted in an obligate heterodimer
through loss of function (with an altered HhH2 domain of
XPF and a degenerated catalytic domain of ERCC1) and
adoption of novel functions (ssDNA and XPA binding
of cERCC1). This permitted additional quality control
mechanisms through a more complicated molecular
interaction network, mediated by the novel functional
domains, and thereby improving the ﬁdelity of DNA
damage repair.
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